This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of TPI 287 in Patients With Advanced Malignancies

This study has been completed.
Information provided by:
Cortice Biosciences, Inc. Identifier:
First received: June 9, 2005
Last updated: June 3, 2009
Last verified: June 2009
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material. The synthesis involves modification to the taxane side chain to overcome multidrug resistance and to achieve mutant tubulin binding. This study will be a multi-center, dose escalation, sequential group, phase I study evaluating the intravenous administration of TPI 287, a novel third generation taxane.

Condition Intervention Phase
Neoplasms Non-Hodgkin Lymphoma Hodgkin Disease Drug: TPI 287 Injection Phase 1

Cortice Biosciences, Inc. has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies

Resource links provided by NLM:

Further study details as provided by Cortice Biosciences, Inc.:

Primary Outcome Measures:
  • To determine the maximum tolerated dose of TPI 287

Secondary Outcome Measures:
  • To determine the safety of TPI 287
  • To determine the antitumor activity of TPI 287
  • To determine the pharmacokinetic profile of TPI 287
  • To determine the pharmacodynamic profile of TPI 287

Estimated Enrollment: 48
Study Start Date: May 2005
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Detailed Description:

The primary objective of this study is to determine the maximum tolerated dose of TPI 287 for phase II clinical trials.

The secondary objectives of the study are:

  • To determine the safety of TPI 287
  • To determine antitumor activity of TPI 287
  • To determine the pharmacokinetic profile of TPI 287
  • To determine the pharmacodynamic profile of TPI 287

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytological evidence of malignancy
  • Patients must have either:

    • advanced solid tumors that have recurred or progressed following standard therapy, or
    • Hodgkin's or non-Hodgkin's lymphoma that has recurred or progressed following standard therapy, have not had a previous bone marrow transplant, and are not eligible for a bone marrow transplant.
  • Failed at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.
  • Ambulatory with ECOG 0 or 1, and a life expectancy of >3 months.
  • Judged by the investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits.
  • Have ability to read, understand and provide written informed consent for the initiation of any study related procedures or have a legal representative to perform this function.
  • If female, must have a negative pregnancy test within 21 days of start of treatment.
  • Agree to the use of an effective method of contraception during the study and for 90 days following the last dose of medication.
  • Patients with prior radiation therapy for brain metastasis or primary brain tumors are acceptable.

Exclusion Criteria:

  • Prior radiation therapy or chemotherapy within 4 weeks (6 weeks for prior nitrosoureas or mitomycin)
  • Another active medical condition(s) or organ disease(s) that may either compromise patient safety or interfere with the safety and/or outcome evaluation of the study drug. While this exclusion is not limited to the following abnormalities, if any of the following laboratory abnormalities are present, the patient should be excluded:

    • WBC < 3000/uL;
    • Absolute neutrophil count < 1500/uL;
    • Platelets < 100,000/uL;
    • Total bilirubin > 1.5 x upper limit of normal;
    • ALT or AST > 3 x upper limit of normal if no liver metastases or >5 upper limit of normal in the presence of liver metastases;
    • Serum creatinine > 1.5 x upper limit of normal;
    • INR >2.0.
  • Patient has clinically significant cardiac co-morbidities or pulmonary impairment
  • Patient or physician plans concomitant chemotherapy, radiation therapy, hormonal and/or biological treatment for cancer including immunotherapy while on study. Of note, therapy with LHRH for prostate cancer is acceptable.
  • Patient has been treated with any investigational drug, investigational biologic, or investigational therapeutic device within 30 days of initiating study treatment.
  • Tumor appears to involve a major artery or vein.
  • Prior or concurrent significant CNS disease including stroke, except for primary or secondary malignancies.
  • Less than 4 weeks since prior major surgery
  • Known positive for HIV, Hepatitis B or C
  • Concurrent chronic use of aspirin (325 mg/day or more)
  • Concurrent or recent (within 1 month) use of thrombolytic agents, or full-dose anticoagulants (except to maintain patency of preexisting, permanent indwelling IV catheters) Of note, therapy with low-molecular weight heparin is acceptable as long as the INR<2.0.
  • Uncontrolled hypertension
  • Grade II-IV peripheral vascular disease within the past year
  • Prior allergic reactions to compounds of similar chemical or biologic composition to TPI 287, paclitaxel or taxotere, Cremophor-EL-P, or other study agents
  • Significant traumatic injury within the past 4 weeks
  • Ongoing or active infection requiring parenteral antibiotics or with a fever >38.1°C within 3 days of the first scheduled day of dosing
  • Other concurrent uncontrolled illness which may interfere with the ability of the patient to participate in the trial
  • Patients who are inpatients
  • Grade II-IV peripheral neuropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00113724

United States, Arizona
Arizona Clinical Research Center
Tucson, Arizona, United States, 85715
United States, Colorado
Rocky Mountain Cancer Center
Denver, Colorado, United States, 80218
United States, District of Columbia
Georgetown University Medical Center/Lombardi Cancer Center
Washington, DC, District of Columbia, United States, 20007-2113
United States, New York
New York Medical College
Valhalla, New York, United States, 10595
Sponsors and Collaborators
Cortice Biosciences, Inc.
Study Director: Michael Kurman, MD Tapestry Pharmaceuticals, Inc.
  More Information

Responsible Party: Tapestry Pharmaceuticals Identifier: NCT00113724     History of Changes
Other Study ID Numbers: TPI 287-01
Study First Received: June 9, 2005
Last Updated: June 3, 2009

Keywords provided by Cortice Biosciences, Inc.:
multi-drug resistance
mutant tubulin binding
Advanced malignancies
Hodgkin's or Non-Hodgkin's Lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on September 19, 2017